Access
This article is part of Nature's premium content.
Published online 12 December 2007 | Nature 450, 935 (2007) | doi:10.1038/450935b
News in Brief: Business
Mutual mouse
Sanofi-Aventis has struck a deal with US biotech firm Regeneron Pharmaceuticals to discover and develop therapies with a genetically engineered 'super-mouse' that can make human antibodies. Under a deal announced on 29 November, the Paris-based drugmaker will pay Regeneron, based in Tarrytown, New York, $85 million up front, and up to $475 million in research and development costs over the next 5 years.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.